vs
Side-by-side financial comparison of MNTN, Inc. (MNTN) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $70.0M, roughly 1.0× MNTN, Inc.). MNTN, Inc. runs the higher net margin — 9.2% vs -49.0%, a 58.2% gap on every dollar of revenue.
MNTN Inc. is a U.S.-headquartered advertising technology firm specializing in performance-driven connected TV (CTV) advertising solutions. It serves e-commerce, retail, and consumer goods brands, helping clients accurately measure ad campaign ROI and reach targeted audiences across streaming TV platforms in North American and European markets.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
MNTN vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.0M | $70.6M |
| Net Profit | $6.4M | $-34.6M |
| Gross Margin | 78.9% | — |
| Operating Margin | 10.8% | -56.7% |
| Net Margin | 9.2% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $70.0M | $70.6M | ||
| Q2 25 | $68.5M | — |
| Q3 25 | $6.4M | $-34.6M | ||
| Q2 25 | $-26.2M | — |
| Q3 25 | 78.9% | — | ||
| Q2 25 | 76.8% | — |
| Q3 25 | 10.8% | -56.7% | ||
| Q2 25 | 5.4% | — |
| Q3 25 | 9.2% | -49.0% | ||
| Q2 25 | -38.3% | — |
| Q3 25 | $0.08 | — | ||
| Q2 25 | $-0.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $179.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $266.7M | $503.0M |
| Total Assets | $335.9M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $179.2M | $490.9M | ||
| Q2 25 | $175.2M | — |
| Q3 25 | $266.7M | $503.0M | ||
| Q2 25 | $238.9M | — |
| Q3 25 | $335.9M | $577.1M | ||
| Q2 25 | $337.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.3M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.45× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $9.3M | $-84.6M | ||
| Q2 25 | $17.6M | — |
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — |
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — |
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — |
| Q3 25 | 1.45× | — | ||
| Q2 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
